肠炎型犬细小病毒病的诊断和防制

本文通过对肠炎型犬细小病毒病的诊断,对病理及其治疗和预防措施等进行分析,并探讨了肠炎型犬细小病毒病的流行特点、症状表现、病理变化及诊断方法,结合实际肠炎型犬细小病毒病的诊断治疗方法和存在的问题进行探讨,切合实际地解决在对犬肠炎型细小病毒病的问题,对犬的生长和发展具有一定的指导意义。     

肠炎型犬细小病毒病的诊治与分析

本文调查了南通某动物医院一年的肠炎型犬细小病毒病例160例,对临床症状、年龄和治疗情况作了详细记录。分析了肠炎型犬细小病毒病的发病与犬的年龄以及月份之间的关系,并统计了肠炎型犬细小病毒病在治疗中使用特异性疗法的治愈率和死亡率,结果表明：犬细小病毒可以感染任何年龄段的犬,但以2～6月龄最易感,3～5月份发病率最高。治疗过程中使用犬细小病毒高免血清,干扰素和犬细小病毒单克隆抗体对提高治愈率有较大的帮助。并针对犬细小病毒病的预防中提出一些建议。     

肠炎型犬细小病毒病的诊治与分析

本文调查了南通某动物医院一年的肠炎型犬细小病毒病例160例,对临床症状、年龄和治疗情况作了详细记录。分析了肠炎型犬细小病毒病的发病与犬的年龄以及月份之间的关系,并统计了肠炎型犬细小病毒病在治疗中使用特异性疗法的治愈率和死亡率,结果表明：犬细小病毒可以感染任何年龄段的犬,但以2～6月龄最易感,3～5月份发病率最高。治疗过程中使用犬细小病毒高免血清,干扰素和犬细小病毒单克隆抗体对提高治愈率有较大的帮助。并针对犬细小病毒病的预防中提出一些建议。     

一例犬细小病毒病的诊断及治疗

犬细小病毒病是犬细小病毒(canine parvovirus)感染犬所引起的一种急性传染病,临床可见肠炎型、心肌炎型和混合型,但以肠炎型多见,可引起未接受疫苗免疫幼犬的大量死亡.本文总结了一例犬细小病毒病继发肠套叠病例的诊断和治疗,以期提高犬细小病毒感染的治愈率.     

犬细小病毒病的诊断与治疗

2011年2～3月武威市某动物医院共接诊53例各类疾病,其中犬瘟热10例,犬细小病毒病18例,犬冠状病毒病5例,其他各种类型的普通病20例。在临床上,犬细小病毒病可分为肠炎型和心肌炎型,本文以一例最为典型的肠炎型犬细小病毒病为例说明对本病的诊断和治疗过程。     

一起犬细小病毒病的诊治报告

犬细小病毒病是国内仅次于犬瘟热的犬类传染病,临床上分为心肌炎型与出血性肠炎型。心肌炎型发病急,得不到治疗而死亡,肠炎型在得到及时诊断与治疗后,能够恢复健康。文中报道一起发生在建宁县濉溪镇大源村某养犬场肠炎型犬细小病毒病的诊治情况。     

一例犬细小病毒性肠炎继发肺水肿的诊治报告

犬细小病毒病是由犬细小病毒引起的犬的一种急性传染病,临床上分为肠炎型和心肌炎型两种,病理特征为出血性肠炎和非化脓性心肌炎。肠炎型的病犬会出现严重的脱水和贫血症状,治疗过程中需大量补液,但有时会因补液量过大或输液速度过快,继发急性肺水肿,造成病犬的死亡。所以,在治疗犬细小病毒病出现继发肺水肿时,应采取积极可行的措施来预防,为进一步提高细小病毒病的治愈率、降低并发症提供临床参考。     

三例史宾格犬肠炎型细小病毒病的诊疗比较

犬细小病毒病是由犬细小病毒感染引起的犬的恶性传染病,各年龄、各品种均易感,2~4月龄幼犬易感性最高,死亡率也最高,症状主要表现为胃肠炎综合征和心肌炎综合征。以三例患有肠炎型细小病毒病的史宾格犬的治疗方案为例,探讨了如何因犬制宜的为患细小病毒病犬制定个体化的治疗方案。     

藏犬细小病毒肠炎型的临床诊断与对症用药

犬细小病毒病是由犬细小病毒引起的犬的一种急性传染病,以出血性肠炎为主要临床特性,8～10周龄犬的感染多以肠炎型为主,近年来,随着养殖藏犬升温,藏犬商用交流增加,各种犬类疾病亦在藏犬之间传播增多,特别是较为难治的犬细小病毒病时有发生。目前藏犬细小病毒病的诊治已有长足的进步,采用对症和中西药联合治疗的方法在临床上取得了令人满意的效果。     

犬肠炎型细小病毒病的临床诊疗

为摸索出一套诊治犬细小病毒病的有效方法和措施,利用快速诊断试纸进行病原学诊断,使本病与肠炎型犬瘟热和犬出血性肠炎得以鉴别诊断.同时用犬细小病毒单克隆抗体代替高免血清进行治疗,并采取适当补充能量和营养剂,及时纠正电解质和酸碱平衡等,能有效提高犬细小病毒病肠炎型的临床治愈率,其治愈率达85%.     

Fatal outbreaks in dogs associated with pantropic canine coronavirus in France and Belgium

Infection with pantropic canine coronavirus was detected during outbreaks in France and Belgium. This was concurrent in most cases with canine parvovirus 2c. One outbreak was a deadly acute systemic disease with a single pantropic canine coronavirus infection. This is the first report of a fatality associated with pantropic canine coronavirus alone outside Italy.     

19例犬细小病毒病的诊疗报告

对某动物医院确诊的19例犬细小病毒病患犬的治疗方法和经验进行汇总、归纳和分析,发现19例均为肠炎型。其中,与寄生虫混合感染的有2例,与冠状病毒感染的有4例,其余13例为单纯犬细小病毒感染。对于细小病毒病患犬要尽早、足量使用抗病毒药物治疗,并配合采取消炎、补液、纠正酸碱失衡等措施是保证疗效的关键。     

复方泛菌克对犬细小病毒病的疗效试验

复方泛菌克是一种新型高效复方抗菌、抗病毒药物,能迅速消除动物的肠毒素和内毒素,增强胃肠吸收能力,提高机体免疫力。犬细小病毒病是犬常见的一种病毒性疾病,易引起溃疡性肠炎和腹泻。现用复方泛菌克对30只患犬细小病毒病的病犬进行治疗,治愈28只,死亡2只,治愈率为93.3%,治疗效果好。     

Influence of long-term treatment with tetracycline and niacinamide on antibody production in dogs with discoid lupus erythematosus

OBJECTIVE: To evaluate the effect of long-term treatment with tetracycline and niacinamide on antibody production in dogs by measuring postvaccinal serum concentrations of antibodies against canine parvovirus and canine distemper virus. ANIMALS: 10 dogs receiving long-term treatment with tetracycline and niacinamide (treatment group) and 10 healthy dogs (control group). PROCEDURE: The treatment group included 9 dogs with discoid lupus erythematosus and 1 dog with pemphigus foliaceus on long-term treatment (> 12 months) with tetracycline and niacinamide. The control group included 10 healthy dogs with no clinical signs of disease and no administered medications for the past 3 months. Blood samples were obtained from all dogs by jugular venipuncture. Serum antibody titers against canine parvovirus and canine distemper virus antigens were measured, using hemaglutination inhibition and serum neutralization, respectively, and compared between groups. RESULTS: A significant difference in antibody titers between treatment- and control-group dogs was not found. All dogs had protective antibody titers against canine distemper virus, and 8 of 10 dogs from each group had protective titers against canine parvovirus infection. CONCLUSION AND CLINICAL RELEVANCE: These results provide evidence that long-term treatment with tetracycline and niacinamide does not interfere with routine vaccinations and thus does not seem to influence antibody production in dogs.     

犬细小病毒病免疫预防研究进展

犬细小病毒病是由犬细小病毒（Canine parvovirus,CPV）引起的一种高度接触性传染病,发病犬临床表现为严重的出血性肠炎和心肌炎综合征。本病全年均有发生,但相对集中在2月～6月份,2月龄～4月龄幼犬易感性最强。病毒主要随污染的饲料、饮水经消化道进入机体引起发病。有些病犬康复后,仍可长期通过粪便排毒,成为本病的重要隐性传染源。一旦发生CPV感染,除早期应用抗血清及对症疗法有效外,无其他特效疗法,中晚期病例多预后不良,因此,必须依靠免疫预防控制该病的发生。本病的预防办法主要是定期进行免疫接种,接种途径主要是肌肉注射。免疫预防要取得满意效果,平时就必须严格执行防疫措施,但免疫的程序与时机等因素都会影响免疫效果。文章就以上内容对犬细小病毒感染免疫预防研究进展做了综述。     

复方参芩对人工感染心肌炎型细小病毒病犬的疗效试验

本试验为探讨复方参芩对人工感染心肌炎型细小病毒病犬的疗效,将犬分为空白对照组、模型组、阳性药物对照组、复方参芩组,用犬细小病毒接种建立动物模型,用复方参芩预防犬细小病毒病,应用生物信号采集系统的心电图技术测定试验动物的心率、心电图,取心脏石蜡包埋、切片、镜检。试验结果显示,攻毒后3 d,模型组犬心率和心电图异常率增加,心肌损害严重;复方参芩组犬心率保持正常,心电图异常率显著低于模型组犬,心肌组织与空白对照组相比差异不显著。试验犬感染病毒第5天,空白对照组犬未出现死亡,模型组犬死亡率为100%,复方参芩组保护率为80%,阳性药物对照组保护率为70%。表明复方参芩能有效预防心肌炎型犬细小病毒病。     

Hematologic improvement in dogs with parvovirus infection treated with recombinant canine granulocyte‐colony stimulating factor

Duffy A., Dow S., Ogilvie G., Rao S., Hackett T. Hematologic improvement in dogs with parvovirus infection treated with recombinant canine granulocyte‐colony stimulating factor. J. vet. Pharmacol. Therap. doi: 10.1111/j.1365‐2885.2009.01153.x. Previously, dogs with canine parvovirus‐induced neutropenia have not responded to treatment with recombinant human granulocyte‐colony stimulating factor (rhG‐CSF). However, recombinant canine G‐CSF (rcG‐CSF) has not been previously evaluated for treatment of parvovirus‐induced neutropenia in dogs. We assessed the effectiveness of rcG‐CSF in dogs with parvovirus‐induced neutropenia with a prospective, open‐label, nonrandomized clinical trial. Endpoints of our study were time to recovery of WBC and neutrophil counts, and duration of hospitalization. 28 dogs with parvovirus and neutropenia were treated with rcG‐CSF and outcomes were compared to those of 34 dogs with parvovirus and neutropenia not treated with rcG‐CSF. We found that mean WBC and neutrophil counts were significantly higher (P < 0.05) in the 28 dogs treated with rcG‐CSF compared to disease‐matched dogs not treated with rcG‐CSF. In addition, the mean duration of hospitalization was reduced (P = 0.01) in rcG‐CSF treated dogs compared to untreated dogs. However, survival times were decreased in dogs treated with rcG‐CSF compared to untreated dogs. These results suggest that treatment with rcG‐CSF was effective in stimulating neutrophil recovery and shortening the duration of hospitalization in dogs with parvovirus infection, but indicate the need for additional studies to evaluate overall safety of the treatment.     

犬细小病毒病发病情况调查与流行分析

对吉林市2009—2010年犬细小病毒病的发病情况进行了调查和分析。收集9个动物医院2年接诊的5684例疑似犬细小病毒病犬,通过临床检查及实验室诊断,确诊4124例患犬发生不同类型的犬细小病毒病。研究表明,本病发生多以肠炎型为主,占总发病数的49.64%;犬品种影响犬细小病毒病的发生,纯种犬的发病率最高,占62.85%,土种犬发病率最低,占11.99%;1~3月龄的幼犬多发,占发病数的65.11%;一年四季均有发病,多发于气温骤变的11~12月和2~3月;免疫次数也影响了犬细小病毒病的发生,每年2次免疫可以显著降低犬细小病毒病的发生。因此,选择高质量的疫苗,增加免疫次数,选择合理的饲养环境,加强多发季节和多发年龄段对犬的保护是减少本病发生的关键。     

中西结合治疗216例犬细小病毒病疗效观察

通过临床症状、流行病学特点和犬细小病毒抗原试剂盒对疑似细小病毒感染的216例病犬进行确诊,并对确诊为细小病毒感染的部分病例进行抗体水平检测,以判断其预后,采用中西结合的综合措施治疗发病犬,治愈率达到70%,提出了有效的预防措施。     

犬细小病毒单克隆抗体对犬细小病毒病的临床应用研究

采用犬细小病毒单克隆抗体（CPVMcAb）配合静脉注射用犬免疫球蛋白及静脉注射用犬血白蛋白,采用股内侧肌肉注射对172例细小病毒病患犬进行临床治疗试验。共治愈140例,治愈率为81．40％。采取以上治疗方案,结合对症支持治疗,发病1d的患犬治愈率90．70％,发病2d的患犬治愈率为85．29％,发病3d的患犬治愈率为56．25％,发病4d的患犬治愈卒为72．73％,发病5、d的患犬治愈率为77．78％。94．29％的治愈犬（132只）用药后4d内完全康复。采用该治疗方案,进入犬体内的McAb能迅速到达全身各组织,中和淋巴组织及血循环中的病毒,阻止病原复制和扩散;同时,中和反应形成抗原抗体复合物,可促进机体的主动免疫反应,促进患犬逐渐康复。该研究结果对提高犬细小病毒病的临床治疗效果具有积极的应用价值。